cholesterol-laden macrophage ''foam'' cells are found in patients with a wide range of lung diseases, 8 it is intriguing to consider that insufficient CYP27A1 product flux, perhaps arising from mitochondrial dysfunction, could be a unifying and perhaps targetable event in human lung disease.
We propose plasma CA as a novel biomarker of AM mitochondrial function during ARDS. However, future studies will be required to verify this postulate. CYP27A1 product flux is expected to also be sensitive to the expression and function of the intracellular proteins that transfer cholesterol into mitochondria. In addition, given that macrophage efflux of sterols other than CA might be favored in the presence of extracellular lipoprotein acceptors, 2 it is conceivable that leakage of plasma lipoproteins into the airspace during lung injury could modify CA flux from AMs.
CA has several features of a robust biomarker. Plasma CA concentrations display little diurnal variation, 9 and unlike other oxysterols, CA is not substantially produced by artefactual autoxidation. 6 Given that the plasma samples we analyzed had been stored at 2808C for approximately 10 years, it appears that CA analysis is robust to long-term storage. Unlike other sterols, CA is not carried on plasma lipoproteins and has no significant correlation with plasma cholesterol levels, 3 suggesting it is not substantially confounded by dyslipidemia. CA also has little to no renal excretion under normal conditions 3 and thus might be little affected during renal failure. Glucocorticoids reportedly upregulate CYP27A1 activity in cell culture, E2 whereas the sedative dexmedetomidine inhibits it E3 ; whether this translates to changes in plasma CA levels in vivo is uncertain. Given that ARDS is commonly associated with multiple comorbidities and therapeutic exposures, future studies will need to carefully address the specificity of changes in plasma CA levels to ARDS pathophysiology.
Taken together, we identify CA as a novel ARDS biomarker. We speculate that plasma CA might represent a valuable new peripheral blood indicator of AM mitochondrial function and propose that it should now be measured in patients with a wider range of lung diseases and potentially in emerging studies of cellbased mitochondrial rescue in the lung. Interferon-induced epithelial response to rhinovirus 16 in asthma relates to inflammation and FEV 1 
To the Editor:
Asthma is a chronic inflammatory airway disease characterized by periodic worsening of asthma symptoms (loss of asthma control or, when more severe, exacerbation), which is often triggered by viral respiratory tract infections, particularly rhinovirus infections. 1 The leading explanations for virus-induced worsening of asthma are an inadequate antiviral response, 2 an exaggerated T H 2 response, 3 or both. Impaired production of innate interferons 2 by primary bronchial epithelial cells (PBECs) in vitro and that of type 1 interferons by bronchoalveolar lavage fluid (BALF) cells from asthmatic patients 4 have been reported, although this was not confirmed by others. 5, 6 Importantly, in vivo data that can clarify the underlying mechanism are still lacking.
We determined whether the transcriptomic profiles of PBECs from patients with mild asthma obtained by means of bronchial brushing before and 6 days after rhinovirus 16 (RV16) challenge, at the peak of respiratory symptoms, 7 is an interferon-driven or T H 2-driven 3 response. Furthermore, we assessed whether the response genes correlated with airway function and inflammation.
Bronchial epithelial brushings were obtained 1 day before and 6 days after RV16 challenge from the RESOLVE (NTR1677) 7 study and the MATERIAL (NCT01520051) study, the setup and time points of which were identical (Fig 1, A) . Patients with allergic asthma were not receiving inhaled or systemic corticosteroids. A detailed description of patients (see Table E1 in this article's Online Repository at www.jacionline.org), inclusion and exclusion criteria, study procedures, RNA isolation, and sequencing are provided in the Methods section in this article's Online Repository at www.jacionline.org.
A total of 174 genes (adjusted P < .05) were differentially expressed between days 21 and 6, of which 131 were enhanced and 43 were attenuated. Gene set enrichment analysis with gene ontology of differentially expressed genes showed highly significant overlap with type I interferon response and defense response gene sets. Analysis of upregulated genes with Interferome v2.01 showed that 15 interferon response genes can be induced by all interferons, 57 by both type I and II interferons, and 4 by type I interferons only (see Fig E1, A, in this article's Online Repository at www.jacionline.org). Interestingly, expression of T H 2 response genes (POSTN, SERPINB2, and CLCA1) was not increased in PBECs 6 days after RV16 exposure (see Fig E1, B) . The heat map shows 21 interferon response genes (selected by using gene set enrichment analysis) with expression that was, on average, 3-fold upregulated in PBECs after RV16 challenge (Fig 1, B) . The z scores of these interferon response genes increased for most patients after RV16 exposure (Fig 1, C) . Ingenuity pathway analysis performed with all differently expressed genes to identify altered pathways showed that both type I and II interferon response signaling pathways were upregulated (Fig 1, D) . Viral loads in BALF cells at day 6 after RV16 challenge (see Fig E2, A, in this article's Online Repository at www.jacionline.org) but not those from nasopharyngeal swabs correlated positively with the increased interferon response gene expression in PBECs (see Fig E2, B) . Similar to our previous study 7 on low-dose (10 median tissue culture infective dose, causing 50% cytopathic effect) RV16 challenge, asthma symptoms (Asthma Control Questionnaire) were increased 6 days after RV16 challenge (Fig 1, E , and see Fig E2, C) , which correlated with z scores of interferon response genes (Fig 1, F) . Expression of IFI6, IFITM1, and IFITM3 after RV16 challenge but not that of other interferon response genes displayed a significant inverse correlation with a drop in FEV 1 (Fig 1, G) . Interferon response gene expression did not correlate with PC 20 values (see Fig E2, D) .
BALF eosinophil cationic protein (ECP) levels (Fig 2, A) but not eosinophil percentages (Fig 2, B) significantly increased after RV16 challenge. There was a strong correlation between percentage eosinophils and interferon response gene expression after RV16 challenge in patients with mild asthma (Fig 2, C) . ECP levels in BALF also strongly correlated with interferon response gene expression after and even before RV16 challenge (Fig 2, D) . Eosinophil counts in blood did not increase at day 6 after RV16 (see Fig E3, A, in this article's Online Repository at www.jacionline.org) but, interestingly, correlated with interferon response genes only after RV16 (see Fig E3, B) . Fraction of exhaled nitric oxide (FENO) levels in exhaled breath did not increase after RV16 (see Fig E3, C) , but a significant positive correlation was seen with interferon response genes only after RV16 challenge (see Fig E3, D) . The BALF neutrophil percentage and myeloperoxidase (MPO) level did not increase after RV16 challenge (see Figs E3 , E and G), and no correlation was observed between neutrophil counts and MPO levels with interferon response genes either before or after RV16 challenge (see Fig E3, F and H) .
Levels of the innate cytokines CXCL10, CXCL8, and IL-6 were significantly increased in BALF after in vivo RV16 challenge (Fig 2, E) . Given that CXCL10 can be induced by interferon, not surprisingly, z scores of interferon response genes positively correlated with the change in CXCL10 levels in BALF after RV16 challenge (Fig 2, F) but not with CXCL8 and IL-6 levels.
Our findings clearly indicate that there is no intrinsic defect in the interferon response in vivo. There was a positive correlation between interferon response gene expression and viral load in BALF cells, indicating that the intensity of the interferoninduced response was dependent on the viral load. Furthermore, interferon response gene expression, but not viral load, correlated with FENO values, lung function parameters, and asthma symptom scores after RV16 challenge. Similarly, eosinophilic inflammation after RV16 challenge, as reflected by eosinophil percentage and ECP level, strongly correlated with interferon-induced responses. Because ECP levels also correlated with interferon-induced responses before RV16 challenge, this is suggestive of a similar underlying process before and after RV16 that is amplified by viral exposure. These above-mentioned correlations are also specific because interferon response gene expression did not correlate with markers of neutrophilic inflammation and PC 20 values.
Together, these data indicate that the interferon response might underlie the drop in FEV 1 , asthma symptoms, FENO values, and eosinophilic responses in asthmatic patients after RV16 exposure. These findings also substantiate the interferon-induced cytokine CXCL10 as an indicator of virus-induced exacerbations. 8 In contrast to earlier reports on viral challenges in asthmatic patients, we found no IL-13-driven response in PBECs at day 6 9 or an increase in BALF neutrophil counts. It is not likely that these differences were due to a difference in atopic status for the present asthmatic patients because skin prick test responses, IgE levels, and blood eosinophil counts were similar to those reported in other studies with RV16 challenges (see Table E1 ). We cannot exclude that the differences are due to the later time point of sampling. Similarly, we cannot exclude an attenuated early interferon response because of sampling at day 6. In fact, we found that IL-33, which was overexpressed in a murine model of virus-induced asthma exacerbations and in PBECs from asthmatic patients 2 days after in vivo RV16 challenge compared with appropriate controls (Ravanetti L, et al, in press), inhibited epithelial innate interferon production. Thus IL-33 might underlie an initial deficient innate antiviral response, which might lead to a late marked interferon-induced gene response.
The Methods section in this article's Online Repository provides data from healthy control subjects who participated in the RESOLVE study. The characteristics of healthy control subjects before and after RV16 are provided in Table E2 and those taken for transcriptomics in Table E3 , in this article's Online Repository at www.jacionline.org. Although based on few samples, at day 6, there is no interferon-induced response in PBECs from healthy control subjects exposed to RV16 in vivo (see the Results section and Fig E4 in this article's Online Repository at www.jacionline. org). Because virus was detected in BALF cells equally in healthy control subjects and patients, we consider it likely that the interferon response in healthy subjects had passed already. Currently, we are sampling 2 days after RV16 challenge in healthy subjects and asthmatic patients to clarify this.
In conclusion, we found a prominent interferon-induced response in PBECs from patients with mild asthma during virus-induced loss of asthma control at day 6. Strikingly, the increased interferon-induced response induced by RV16 relates to the drop in FEV 1 , increased Asthma Control Questionnaire scores, and enhanced airway inflammation (CXCL10 and ECP).
We thank Dr K. van der Sluijs for initiating several RV16 studies from which material was obtained for the current study. E. J. M. Weersink, MD, is gratefully acknowledged for her independent medical supervision. We thank Dr Marianne van de Pol for recruiting patients and performing some of the rhinovirus challenge in the studies. We sincerely thank Tamara Dekker, BSc, and Barbara Dierdorp, BSc, for their BALF cell counting and Ebru Damadoolu, MD, for initial staining of cytospin preparations of BALF cells. We thank David van der Meer and Dr Andr e Wijfjes from GenomeScan, Leiden, The Netherlands, for performing the transcriptome analyses. We also thank Dr Brendon P. Scicluna (Center for Experimental and Molecular Medicine, AMC) for providing access to the ingenuity pathway analysis platform. We sincerely thank Dr Richard Volckmann from the Department of Oncogenomics, Academic Medical Center, for helping with submission of data sets to the GEO genomics data repository. We are very grateful to all patients for their participation in the present studies; without their commitment and suggestions, this study would not have been possible. clinical assessment. B, Heat maps of 21 interferon response genes in PBECs from patients with mild asthma (n 5 15) before and 6 days after RV16. The intensity of average gene expression is represented as z scores below the heat maps (blue for low and red for high gene expression). C, As for Fig 1, B , z scores of interferon response genes were plotted per patient. **P < .01, paired t tests. D, Ingenuity pathway analysis for differentially expressed genes in asthma PBECs. Red and gray nodes represent upregulated genes, and white nodes represent genes that were not differentially expressed but are in the pathway. E, Asthma Control Questionnaire (ACQ) scores increased in patients with mild asthma (n 5 15) at day 6 after RV16 challenge compared with baseline. **P < .01, paired t tests. F, Interferon response gene expression after RV16 challenge positively correlated with ACQ scores at day 6 after RV16. G, Changes (D) in IFI6, IFITM1, and IFITM3 expression in PBECs after RV16 infection correlated with changes (D) in FEV 1 percentage after RV16 challenge compared with before RV16 (n 5 15). All correlations were done by using the Pearson correlation coefficient. *P < .05. (Fig 2, A) and percentage of BALF eosinophils (Fig 2,  B) before and after RV16 challenge (n 5 15). **P < .01, paired t tests. C and D, Interferon response genes correlated with eosinophils percentages (Fig 2, C) and ECP values (Fig 2, D) after RV16 challenge (n 5 15). E, Levels of the BALF innate cytokines CXCL10 (n 5 15), CXCL8 (n 5 14), and IL-6 (n 5 14) before and after RV16 challenge. *P < .05 and **P < .01, paired t tests. F, z Scores for interferon response genes correlated with change in BALF CXCL10 levels after RV16 challenge (n 5 15). All correlations were done with the Pearson correlation coefficient. **P < .01 and ***P < .001. ns, Not significant. Hsa-mir-144-3p expression is increased in umbilical cord serum of infants with atopic dermatitis
To the Editor: Atopic dermatitis (AD) is a common chronic inflammatory disease of childhood. Up to 60% of cases appear during the first year of life, and most resolve during the first few years. 1 The skin of patients with AD is characterized by several abnormalities in barrier function, including altered lipid composition, decreased number of tight junctions, altered protease activity, and altered antimicrobial activity. 2 The dual exposure to allergen hypothesis suggests that tolerance to antigens occurs in the neonate through high-dose oral exposure and allergen sensitization occurs through low-dose cutaneous exposure. 3 This makes AD a gateway for the allergic march, highlighting the importance of preventing infantile AD. However, little is known about the initial changes that specifically occur in keratinocytes and lead to barrier dysfunction. MicroRNAs (miRNAs), which are short noncoding RNAs involved in posttranscriptional gene regulation, have been implicated in the pathogenesis of many diseases, including allergic diseases. 4 In this study we aimed to understand whether serum miRNAs expressed in the perinatal period could influence the development of AD in infancy.
The samples for this study were obtained from a birth cohort at high risk for allergic diseases (unpublished data). Details of the cohort study are provided in the Methods section in this article's Online Repository at www.jacionline.org. To identify miRNA changes seen in maternal serum (MS) and umbilical cord serum (CS) of children with AD, we selected a nested case-control population of 36 children who did (AD) or did not (No AD) have AD at 1 year of age and their mothers using propensity score matching. The baseline characteristics of the infants and their mothers in the nested case-control population were similar to those of the cohort population (see Tables E1 and E2 in this article's Online Repository at www.jacionline.org).
First, we determined the expression levels of 179 miRNAs in CS and MS using quantitative PCR (qPCR). The pool of change in cycle threshold (dCt) values obtained from qPCR was subjected to Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) to understand the association between miRNAs in CS and MS and to distinguish between miRNAs that might or might not be associated with AD. Fig 1, A, shows the distinct expression patterns of miRNAs in CS and MS, describing 32.7% (R2X 5 0.327) of the variation in X and 96.3% (R2Y 5 0.963) of the variation in Y and predicting 93.3% (Q2Y 5 0.933) of the variation in Y. Because OPLS-DA analysis could not distinguish miRNA profiles for the AD and No AD groups, we analyzed miRNAs in CS and MS separately and identified 24 miRNAs in CS and 23 in MS with a variable importance in projection (VIP) score of 1.5 or more that were independently associated with the development of AD (Fig 1, B , and see Table E3 in this article's Online Repository at www.jacionline.org).
Because there was no association between miRNA expression in MS and CS, suggesting that maternal miRNAs might not have a direct effect on the baby (see Fig E1 in this article' s Online Repository at www.jacionline.org), we further evaluated the candidate miRNAs in CS. Comparison of their expression levels in the AD and No AD groups showed that hsa-miR-144-3p (miR-144) expression was increased in CS of children with AD at 1 year of age. This change was not seen in MS or in serum at 1 year of age (Fig 1, C) . As miR-144 expression in CS was not associated with total IgE levels at 1 year of age (see Fig E2 in this article's Online Repository at www.jacionline.org), miR-144 might play a role in the pathogenesis of AD independent of atopic status. Therefore we focused on the role of miR-144 in keratinocytes.
Using Web-based software (microRNA.org, TargetScan, and miRBase), we identified ATP-binding cassette transporter A1 (ABCA1) as a target of miR-144. ABCA1 is involved in cholesterol efflux from cells, and miR-144 has been shown to downregulate ABCA1 levels, leading to cholesterol accumulation within cells. 4 To observe the effect of miR-144 on ABCA1 mRNA expression in keratinocytes, we transfected neonatal human primary epithelial keratinocytes (referred to hereafter as keratinocytes) with miR-144. Transfected keratinocytes showed decreased ABCA1 mRNA expression (see Fig E3, A, in this article's Online Repository at www.jacionline.org), decreased ABCA1 protein levels, and cholesterol accumulation (see Fig E3, B) , demonstrating the role of miR-144 in disrupting the cholesterol composition of the cell membrane in keratinocytes.
ABCA1 knockout in macrophages has been shown to exaggerate cytokine responses to TLR agonists through nuclear
METHODS
Parallel to the study with asthmatic patients, 11 healthy control subjects from the RESOLVE study (NCT1677) were subjected to RV16. The characteristics of the healthy control subjects are provided in Table E2 . Unfortunately, we could determine the transcriptomic profile in PBECs from 4 healthy subjects before and 6 days after RV16 challenge only. This was due to inappropriate handling of the samples and not the low quality of the RNA samples obtained from the control subjects. The characteristics of 4 healthy control subjects taken for transcriptomics are provided in Table E3 .
Study procedures
Prebronchodilator FEV 1 was measured by using standard spirometry, according to the recommendations of the European Respiratory Society. E1 The drop in FEV 1 was determined based on the change in FEV 1 percent predicted after RV16 challenge compared with FEV 1 percent predicted before RV16 at baseline. Methacholine bronchoprovocation tests using the standard tidal volume method with a maximum dose of 16 mg/mL were done to measure PC 20 values. E2 BALF and bronchial brushings were collected by using standard bronchoscopic procedures. E3 BALF recovery (73% 6 6.6% [mean 6 SD]) was similar in patients and healthy control subjects, allowing for direct comparison. The 73% recovery is in line with the 68% recovery in our routine diagnostics that we obtain for 8 subsequent washes with 20 mL of saline. FENO values were measured with a chemiluminescence analyzer. E4 CXCL10, CXCL8, and IL-6 levels were determined by using Luminex, according to the manufacturer's protocol (Bio-Rad Laboratories, Veenendaal, The Netherlands). ECP and MPO levels were measured by means of ELISA, as described previously. E5 Rhinovirus was detected by means of quantitative PCR in the nasal swabs and BALF cells collected 6 days after RV16 infection.
E6

Subjects
The study protocols were reviewed and approved by the ethical review committee and were in accordance with the Declaration of Helsinki. All patients and control subjects provided written informed consent. The studies were conducted in 1 center only at the Department of Respiratory Medicine of the Academic Medical Center, Amsterdam, The Netherlands. Ten patients with mild asthma and all healthy control subjects were from the RESOLVE study, and 5 patients with mild asthma were from the MATERIAL study. PBECs from asthmatic patients in the MATERIAL study were obtained only from patients in the placebo group. Patients with mild allergic asthma met the following criteria: a history of episodic chest symptoms, baseline FEV 1 of greater than 80% of predicted value, airway responsiveness to methacholine (provocative concentration causing a 20% fall in FEV 1 , PC 20 < 9.8 mg/ mL), and a positive skin prick test response to at least 1 of 10 common aeroallergens. We cannot exclude a bias in terms of male/female ratio in patients with mild asthma.
The study design for healthy control subjects is similar to that of patients with mild asthma. Healthy subjects had an FEV 1 of greater than 80% of predicted value, a PC 20 value of greater than 16 mg/mL, and negative skin prick test responses to 12 common aeroallergens.
To determine the atopic status of these patients, skin prick tests were done with 10 locally relevant aeroallergens: grass mix, tree mix, house dust mite, cats, dogs, Alternaria alternatum, Aspergillus fumigatus, Cladosporium herbarum, latex, and rabbit (ALK-Abell o, Hørsholm, Denmark). All volunteers were aged between 18 and 40 years, were nonsmokers or had stopped smoking 12 months ago with 5 or fewer pack years of smoking, had negative results for serum neutralizing antibodies against RV16 (1 in 4 or fewer), and did not have concomitant disease or a (chronic) inflammatory condition that would interfere with this study according to the judgment of a pulmonary physician. Volunteers with an underlying viral airway infection on day 1, as determined by using PCR on nasal swabs, were withdrawn from the study. The criteria for successful infection are at least one of these: RV16 seroconversion, positive Common Cold Score, or detection of rhinovirus in nasal swab or lavage fluid.
RNA isolation and sequencing
The brushings, which consisted predominantly (>95%) of PBECs, were pooled (2 brushes for each sample) and centrifuged at 1240 rpm (Rotanta 460S) for 10 minutes at 48C. The pellet was dissolved in 1 mL of TRIzol and stored at 2808C until RNA was isolated. After all samples were obtained, they were thawed at room temperature, and after 200 mL of chloroform was added, they were shaken vigorously for 30 seconds. Samples were kept at room temperature for 10 minutes and centrifuged at 16,000g for 15 minutes at 48C. The aqueous phase was cleaned up and concentrated with protocol 5.3 by using the Nucleospin RNA XS Extraction Kit (Macherey-Nagel, Bethlehem, Pa). No carrier RNA was added because it would interfere with RNA sequencing.
The quality and concentration of the samples were assessed by using a fragment analyzer (Advanced Analytical Technologies, Ankeny, Iowa). RNA from 4 brushings from healthy control subjects was of sufficient quality for transcriptomic analysis. A data set consisting of 38 samples was sequenced on an Illumina NextSeq 500 sequencer (Illumina, San Diego, Calif).
cDNA preparation and RNA sequencing
The NEBNext Ultra Directional RNA Library Prep Kit from Illumina was used to process the samples. Sample preparation was performed according to the NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB #7420S/ L) protocol. Briefly, oligo-dT magnetic beads were used to isolate mRNA from total RNA. cDNA synthesis was performed after fragmentation of this mRNA. This was used for ligation with sequencing adapters, followed by PCR amplification of the resulting product. Quality and yield after sample preparation were measured with the fragment analyzer. The size of the resulting products was consistent with the expected size distribution between 300 and 500 bp.
Raw data were sampled and mapped to annotated genomic references to evaluate the quality of the library preparation and kits used. Mapping positions were classified as intragenic, exonic, intergenic, intronic, and rRNA. Clustering and DNA sequencing were performed according to the manufacturer's protocol by using the Illumina NextSeq 500. A concentration of 1.6 pmol/L was used as input. The reads were trimmed for adapter sequences with Trimmomatic v0.30 before alignment. Presumed adapter sequences were removed from the read when the bases matched a sequence in the adapter sequence set (TruSeq adapters) with 2 or fewer mismatches and an alignment score of at least 12. The reference of Homo_sapiens.GRCh37.75 was used to align the reads. Mapping to the reference sequence was done with a short reader aligner based on Burrows-Wheeler transformation. A default mismatch rate of 2% (3 mismatches in a read of 150 bases) was used.
Sequence data analysis
The frequency of the reads mapped on the transcript was determined as counts, which is used as an input for downstream analysis. Additionally, reads/ fragments per kilobase of exon per million reads mapped were calculated. Read counts were loaded into the DESeq2 package, a statistical package within the R/ Bioconductor platform to determine differentially expressed genes (paired). Image analysis, base calling, and quality checks were performed with the Illumina data analysis pipeline RTA v2.4.11 and Bcl2fastq v2.17. z Scores used for correlations are calculated in log 2 gene expression values, where the average (of the cohort) is subtracted from every sample value and divided by the SD (of the cohort). Data sets can be accessed in the Gene Expression Omnibus at https:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc5GSE106388.
RESULTS
Interferon response genes were not enhanced in healthy control subjects at day 6 after RV16 challenge Contrary to what was found for PBECs from patients with mild asthma, interferon response gene expression showed no increase in PBECs from healthy control subjects after RV16 challenge at day 6 (Fig E4) .
FIG E1.
Type of interferon response in PBECs from patients with mild asthma after RV16 and that of the IL-13-driven T H 2 response genes in patients with mild asthma and healthy control subjects. A, The Venn diagram represents the type of interferons that can induce interferon response genes in PBECs after RV16. B, The z score of T H 2 response genes (CLCA1, POSTN, and SERPINB2) plotted individually did not significantly differ before and after RV16 challenge in patients with mild asthma (n 5 15) and heathy control subjects (n 5 4). ns, Not significant. A, Viral copies measured in BALF cells from healthy subjects (n 5 11) and patients with mild asthma (n 5 15) did not differ 6 days after RV16 challenge. B, Viral load in BALF cells correlated positively with z scores of interferon response genes, but no correlation was observed with viral load in the nasal swab (n 5 15). **P < .01, Pearson correlation analysis. C, Asthma Control Questionnaire (ACQ) scores measured at day 1 before RV16 and 6 and 13 days after RV16 (n 5 15). D, There was no correlation observed between log 2 PC 20 values, reflecting airway hyperresponsiveness, and interferon response gene expression before and after RV16 challenge (Pearson correlation analysis). ns, Not significant.
FIG E3.
Blood eosinophil counts, FENO values, BALF neutrophil counts, and MPO levels before and after RV16 and their correlation with interferon response gene expression. A, Blood eosinophil counts did not increase at day 6 after RV16 in patients with mild asthma (n 5 15). B, Interferon response gene expression correlated with blood eosinophil counts only after RV16 in patients with mild asthma. C, FENO values were increased in patients with mild asthma at baseline but did not significantly differ before and after RV16 challenge in both patients with mild asthma (n 5 15) and healthy control subjects (n 5 12). **P < .01 and ***P < .001, unpaired t tests. D, Interferon response gene expression in PBECs also correlated with FENO values more significantly after RV16 challenge in patients with mild asthma (n 5 15). **P < .01, Pearson correlation analysis. E and F, Percentage of neutrophils in BALF did not change (Fig E3, E) and did not correlate with interferon response gene expression (Fig E3, F) before and after RV16 challenge in patients with mild asthma (n 5 15). G, MPO levels in BALF were not altered significantly before and after RV16 challenge (n 5 15). H, Interferon response gene expression did not correlate with MPO levels before and after RV16 challenge (n 5 15). ns, Not significant.
FIG E3. (Continued).
FIG E4.
PBECs from healthy control subjects show no enhanced interferon response gene expression after RV16 at day 6. A, Heat maps of interferon responses gene expression in PBECs from healthy control subjects before and 6 days after in vivo RV16 exposure (n 5 4). B, No differences were observed in z scores of interferon response gene expression plotted per healthy control subject (n 5 4). 
